05/12/2017 | Press release | Distributed by Public on 05/12/2017 11:05
To qualify for the Target: Stroke Honor Roll, hospitals must meet quality measures developed to reduce the time between stroke patients' arrival and treatment with the clot-buster tissue plasminogen activator, or tPA, the only drug approved by the U.S. Food and Drug Administration to treat ischemic stroke. If given intravenously in the first three hours after the start of stroke symptoms, tPA can significantly reduce the effects of stroke and lessen the chance of permanent disability.
Swedish Covenant Hospital earned the award by meeting specific required guidelines for the diagnosis and treatment of stroke patients. 'A stroke patient loses 1.9 million neurons each minute stroke treatment is delayed,' said Katie Lord, Swedish Covenant Hospital's stroke program coordinator. 'This recognition further demonstrates our ability to deliver quality stroke treatments to patients quickly and safely. We continue to strive for excellence in the acute treatment of stroke patients.'
'The American Heart Association and American Stroke Association recognize Swedish Covenant Hospital for its commitment to stroke care,' said Paul Heidenreich, M.D., M.S., national chairman of the Get With The Guidelines Steering Committee and Professor of Medicine at Stanford University. 'Research has shown there are benefits to patients who are treated at hospitals that have adopted the Get With The Guidelines program.'
According to the American Heart Association/American Stroke Association, stroke is the No. 5 cause of death and a leading cause of adult disability in the United States. On average, someone in the U.S. suffers a stroke every 40 seconds, someone dies of a stroke every four minutes, and nearly 800,000 people suffer a new or recurrent stroke each year.